Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
S
Shotlee
Health & Wellness Team
1 min read
Preparing your Shotlee experience
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
A safety warning regarding the potential risk of suicidal ideation and behaviors associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.
The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, diminishing the efficacy of oral contraceptives could not be dismissed.
According to the TGA's safety alert, updated product warnings have been issued for this class of prominent medications. These drugs are formally utilized in Australia for managing type 2 diabetes and obesity, and the update follows investigations conducted by international regulatory bodies.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from WAtoday
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨